With an extensive patent portfolio, Oryzon Genomics is the biotechnology leader in Spain and the leading epigenetics company in Europe.

Read more

Oryzon is the leader in the development of therapeutics in the epigenetic target LSD1: Oryzon has a program in oncology, iadademstat (ORY-1001), in Phase IIa in leukemia and in small cell lung cancer (SCLC), another program in the field of neurodegenerative and neuroinflammatory diseases, vafidemstat (ORY-2001), with multiple Phase IIa trials in, Alzheimer's disease, multiple sclerosis and aggressiveness in psychiatric and neurodegenerative diseases, and a third program, ORY-3001, currently finishing the preclinical regulatory phase, focused on the treatment of non-oncological diseases.

Oryzon also has other programs at early preclinical stage in other epigenetic therapeutic targets.

Interview to Carlos Buesa, Chief Executive Officer, and Roger Bullock, Chief Medical Officer.
Source: EdisonTV.  November 21^st, 2018

Invited to present at Investing in Oncology Forum 2019 in Stockholm.

CEO Carlos Buesa, at the Investment in Oncology Forum in Stockholm, October 7th 2019

See source with presentation included